Current clinical pharmacology最新文献

筛选
英文 中文
Meet Our Editorial Board Member 见见我们的编辑委员会成员
IF 3.2
Current clinical pharmacology Pub Date : 2019-12-31 DOI: 10.2174/157488471403191231122122
Georgescu Adriana
{"title":"Meet Our Editorial Board Member","authors":"Georgescu Adriana","doi":"10.2174/157488471403191231122122","DOIUrl":"https://doi.org/10.2174/157488471403191231122122","url":null,"abstract":"","PeriodicalId":10746,"journal":{"name":"Current clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2019-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49168122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral and Intra-nasal Administration of Nanoparticles in the Cerebral Ischemia Treatment in Animal Experiments: Considering its Advantages and Disadvantages 口服和鼻内给药纳米颗粒治疗脑缺血的动物实验:考虑其优缺点
IF 3.2
Current clinical pharmacology Pub Date : 2019-12-31 DOI: 10.2174/22123938otkzpotu1tcvy
Firoozeh Alavian and Nasrin Shams
{"title":"Oral and Intra-nasal Administration of Nanoparticles in the Cerebral Ischemia Treatment in Animal Experiments: Considering its Advantages and Disadvantages","authors":"Firoozeh Alavian and Nasrin Shams","doi":"10.2174/22123938otkzpotu1tcvy","DOIUrl":"https://doi.org/10.2174/22123938otkzpotu1tcvy","url":null,"abstract":"","PeriodicalId":10746,"journal":{"name":"Current clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2019-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48352308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Prevalence and Predictors of Self-Medication Practices in India: 
A Systematic Literature Review and Meta-Analysis 印度自我药物治疗的患病率和预测因素:
系统文献综述和荟萃分析
IF 3.2
Current clinical pharmacology Pub Date : 2019-11-21 DOI: 10.2174/1574884714666191122103953
Muhammed Rashid, M. Chhabra, A. Kashyap, K. Undela, S. K. Gudi
{"title":"Prevalence and Predictors of Self-Medication Practices in India: \u2028A Systematic Literature Review and Meta-Analysis","authors":"Muhammed Rashid, M. Chhabra, A. Kashyap, K. Undela, S. K. Gudi","doi":"10.2174/1574884714666191122103953","DOIUrl":"https://doi.org/10.2174/1574884714666191122103953","url":null,"abstract":"Background Self-Medication (SM) is a practice of using medications to treat self-diagnosed symptoms without a legitimate prescription by a health care professional. Alongside posing a burden on a patient, SM practices are associated with certain unfavourable health conditions such as drug-resistance, adverse effects, drug-interactions, including death. Objective To systematically review and quantify the prevalence of SM practices and its associated factors in India. Methods A comprehensive systematic search was performed using scientific databases such as PubMed and Cochrane library for the peer-reviewed research articles that were conducted in India without any language and date restrictions. Studies which were cross-sectional by design and assessing the prevalence and predictors of SM practices in India were considered for the review, and all the relevant articles were screened for their eligibility. Results Of 248 articles, a total of 17 articles comprising of 10,248 participants were included in the meta-analysis. Overall, the mean prevalence of SM practices in India was observed to be 53.57%. Familiarity with the medication appears to be a major reason to practice SM (PR: 30.45; 95% \u2028Confidence Interval [CI]: 17.08-43.82; 6 studies), and the practice was noticed more among \u2028individuals from a middle-lower class family with a prevalence rate of 26.31 (95%CI: 2.02-50.60; P<0.0001). Minor ailments were the primary reason for practicing SM (PR: 42.46; 95%CI: 21.87-63.06), among which headache was the most commonly reported (PR: 41.53; 95%CI: 18.05-65.02). Conclusion Self-medication practices are quite frequent in India. While NSAIDs and anti-allergens are the most frequently utilized self-medicated drugs used for headache and cold and cough.","PeriodicalId":10746,"journal":{"name":"Current clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2019-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574884714666191122103953","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43551669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 19
Effects of Probiotics and Prebiotics on Frailty and Ageing: A Narrative Review. 益生菌和益生素对虚弱和衰老的影响:叙述性综述。
IF 3.2
Current clinical pharmacology Pub Date : 2019-11-20 DOI: 10.2174/1574884714666191120124548
Kulapong Jayanama, O. Theou
{"title":"Effects of Probiotics and Prebiotics on Frailty and Ageing: A Narrative Review.","authors":"Kulapong Jayanama, O. Theou","doi":"10.2174/1574884714666191120124548","DOIUrl":"https://doi.org/10.2174/1574884714666191120124548","url":null,"abstract":"Globally, the population over the age of 60 is growing fast, but people age in different ways. Frailty, shown by the accumulation of age-related deficits, is a state of increased vulnerability to adverse outcomes among people of the same chronological age. Ageing results in a decline in diversity and homeostasis of microbiomes, and gut flora changes are related to health deficit accumulation and adverse health outcomes. In older people, health deficits including inappropriate intake, sarcopenia, physical inactivity, polypharmacy, and social vulnerability are factors associated with gut dysbiosis. The use of probiotics and prebiotics is a cost-effective and widely available intervention. Intake of probiotics and prebiotics may improve the homeostasis of gut microflora and prevent frailty and unhealthy aging. However, health effects vary among probiotics and prebiotics and among individual populations. This narrative review summarizes recent evidence about the relationship of prebiotic and probiotic consumption with health outcomes in older people.","PeriodicalId":10746,"journal":{"name":"Current clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2019-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574884714666191120124548","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46101394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 19
Tenofovir urine assay to monitor adherence to HIV pre-exposure prophylaxis (PrEP). 替诺福韦尿检测监测HIV暴露前预防(PrEP)依从性。
IF 3.2
Current clinical pharmacology Pub Date : 2019-11-11 DOI: 10.2174/1574884714666191111125348
G. Moorthy, L. Lalley-Chareczko, H. Koenig, A. Zuppa
{"title":"Tenofovir urine assay to monitor adherence to HIV pre-exposure prophylaxis (PrEP).","authors":"G. Moorthy, L. Lalley-Chareczko, H. Koenig, A. Zuppa","doi":"10.2174/1574884714666191111125348","DOIUrl":"https://doi.org/10.2174/1574884714666191111125348","url":null,"abstract":"BACKGROUND\u0000Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are prodrugs of tenofovir and have excellent long-term efficacy and tolerability for the treatment of HIV. An objective marker of adherence to tenofovir-based therapy could be clinically useful in supporting adherence to TDF-based HIV pre-exposure prophylaxis (PrEP) in populations in whom self-report has been shown to be unreliable, and could play a role in resource-limited settings to support HIV and hepatitis B treatment adherence.\u0000\u0000\u0000METHODS\u0000A semi-quantitative high-performance liquid chromatography-mass spectrometry method for tenofovir quantification of urine samples was developed. This assay detects tenofovir concentration in log10 levels between 1 and 10,000 ng/mL, and was shown to distinguish between recent adherence and low/non-adherence to both TDF and TAF, with a concentration of >1000 ng/mL highly predictive of medication ingestion in the last 24-48 hours.\u0000\u0000\u0000RESULTS\u0000This assay was validated relative to other markers of adherence including dried blood spot and self-report in a highly adherent population of PrEP patients, and tenofovir was shown to be stable at room temperature in urine for at least 14 days. The assay was successfully used in a clinical setting to maintain high PrEP adherence and retention in care in 50 young men who have sex with me (MSM) over 48 weeks, to assess PrEP adherence in youth with mental health conditions, and to monitor drug levels relative to plasma levels in a case study of chewed TDF/FTC (tenofovir/emtricitabine) for PrEP.\u0000\u0000\u0000CONCLUSION\u0000The findings of this review confirm the utility of tenofovir urine assay to monitor adherence to HIV pre-exposure prophylaxis. Further studies are underway to implement the tenofovir urine assay to monitor adherence and pre-exposure prophylaxis, nationally and internationally.","PeriodicalId":10746,"journal":{"name":"Current clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2019-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574884714666191111125348","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46540310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Meet Our Editorial Board Member 会见我们的编辑委员会成员
IF 3.2
Current clinical pharmacology Pub Date : 2019-10-25 DOI: 10.2174/157488471402190906102203
R. Mehvar
{"title":"Meet Our Editorial Board Member","authors":"R. Mehvar","doi":"10.2174/157488471402190906102203","DOIUrl":"https://doi.org/10.2174/157488471402190906102203","url":null,"abstract":"","PeriodicalId":10746,"journal":{"name":"Current clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2019-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46765970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Formulation and evaluation of polyherbal cream and lotion to treat psoriasis-induced secondary infections. 多羟基乳膏和洗剂治疗银屑病继发感染的配方和评价。
IF 3.2
Current clinical pharmacology Pub Date : 2019-10-17 DOI: 10.2174/1574884714666191017111218
P. Joshi, Sushil Joshi, Urvashi Rajani, R. Semwal, D. Semwal
{"title":"Formulation and evaluation of polyherbal cream and lotion to treat psoriasis-induced secondary infections.","authors":"P. Joshi, Sushil Joshi, Urvashi Rajani, R. Semwal, D. Semwal","doi":"10.2174/1574884714666191017111218","DOIUrl":"https://doi.org/10.2174/1574884714666191017111218","url":null,"abstract":"BACKGROUND\u0000Psoriasis is one of the most common skin diseases in human and affected a major population worldwide. Aim: The aim of the present study is to evaluate the efficacy of selected polyherbal formulations against psoriasis-induced secondary infections. Methods: Samples were collected from the scalp, behind the ears, chest and back of the patients. The microscopic examination of fungal and bacterial growth was carried out with lactophenol cotton blue stain and gram stain respectively. Volatile constituents of essential oils were identified by GC-MS analysis, in order to investigate the relation between chemical composition and biological activity. Nutrient agar media was used for antibacterial activity whereas Sabourauds dextrose agar media was used for antifungal activity. Results: A total of 24 isolates were obtained from 2 patient of scalp psoriasis. Anti-oxidant activity of the samples was determined using DPPH radical scavenging method. In the present study, EOs showed a good antifungal action against Malassezia pachydermatis and other microbial strains. The GC-MS analysis revealed the presence of eugenol, linalool, citral, neral, limonene, terpenes, eucalyptol and thymol in the essential oils. The formulated retention lotion 1 (L4), 2 (L5), 3 (L6) and cream 1 (C1) showed DPPH radical scavenging activity by 23.52%, 24.48%, 28% and 5.08%, respectively. Conclusion: The present study concluded that most of the formulated lotions and creams showed good antimicrobial activity and may be applied topically against scalp psoriasis.","PeriodicalId":10746,"journal":{"name":"Current clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2019-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574884714666191017111218","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45738826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Meet Our Editorial Board Member 会见我们的编辑委员会成员
IF 3.2
Current clinical pharmacology Pub Date : 2019-03-13 DOI: 10.2174/157488471401190301120023
F. Kugawa
{"title":"Meet Our Editorial Board Member","authors":"F. Kugawa","doi":"10.2174/157488471401190301120023","DOIUrl":"https://doi.org/10.2174/157488471401190301120023","url":null,"abstract":"","PeriodicalId":10746,"journal":{"name":"Current clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2019-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/157488471401190301120023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46889807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Concomitant Use of Cotrimoxazole and Atazanavir in HIV-infected Patients: A Therapeutic Drug Monitoring and Pharmacovigilance Based Dual Approach. 复方新诺明和阿扎那韦在hiv感染者中的联合应用:一种基于药物监测和药物警戒的双重方法。
IF 3.2
Current clinical pharmacology Pub Date : 2019-01-01 DOI: 10.2174/1574884714666190405160612
Miantezila B Joe, Landman Roland, Chouchana Laurent, Lê M Patrick, Olivier Sawoo, Tona L Gaston, Eto Bruno, Peytavin Gilles, Pochart Philippe
{"title":"Concomitant Use of Cotrimoxazole and Atazanavir in HIV-infected Patients: A Therapeutic Drug Monitoring and Pharmacovigilance Based Dual Approach.","authors":"Miantezila B Joe,&nbsp;Landman Roland,&nbsp;Chouchana Laurent,&nbsp;Lê M Patrick,&nbsp;Olivier Sawoo,&nbsp;Tona L Gaston,&nbsp;Eto Bruno,&nbsp;Peytavin Gilles,&nbsp;Pochart Philippe","doi":"10.2174/1574884714666190405160612","DOIUrl":"https://doi.org/10.2174/1574884714666190405160612","url":null,"abstract":"<p><strong>Background: </strong>Cotrimoxazole is the main antibiotic used in primary prophylaxis for opportunistic infections in advanced HIV infection. This drug can inhibit one of the metabolic pathways of atazanavir (ATV), such as the cytochromes P450 (CYP) 2C8/2C9 and could interfere with its safety and efficacy.</p><p><strong>Objective: </strong>We studied the drug-drug interaction (DDI) between cotrimoxazole and ATV by using therapeutic drug monitoring (TDM) and pharmacovigilance (PV) approaches.</p><p><strong>Methods: </strong>We compared a group of patients treated with cotrimoxazole and receiving an ATV-based regimen to controls. This historical cohort analysis used data from Dat'AIDS in HIV-infected patients who had at least two lowest plasma concentrations (C-trough) of ATV during their outpatient follow-up. Likewise, we used the international pharmacovigilance data from VigiBase to evaluate the notifications of hyperbilirubinemia reported with ATV.</p><p><strong>Results: </strong>In the TDM analysis, the two groups of patients (treated with cotrimoxazole and controls) were almost homogeneous concerning the main baseline features. After at least six months of ATVbased regimen, there was no significant difference in the safety threshold of the ATV C-trough [with an adjusted odds ratio (aOR) of 1.4 (95% CI: 0.5 - 4.4)] compared to controls. We observed similar results with the efficacy thresholds of ATV C-trough. Regarding the PV analysis, there was no difference in hyperbilirubinemia occurring with ATV when cotrimoxazole was concomitant, with an adjusted reporting odds ratio (aROR) of 0.9 (95% CI: 0.6 to 1.2).</p><p><strong>Conclusion: </strong>This study showed a relevant concomitant use between Cotrimoxazole and ATV based on TDM and PV approaches.</p>","PeriodicalId":10746,"journal":{"name":"Current clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574884714666190405160612","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37132450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Possibility of Therapeutic Drug Monitoring of the Most Important Interactions in Nursing Homes. 疗养院中最重要相互作用的治疗药物监测的可能性。
IF 3.2
Current clinical pharmacology Pub Date : 2019-01-01 DOI: 10.2174/1574884714666181224144722
Pernille Schjøtt, Martina Šutovská, Jan Schjøtt
{"title":"The Possibility of Therapeutic Drug Monitoring of the Most Important Interactions in Nursing Homes.","authors":"Pernille Schjøtt,&nbsp;Martina Šutovská,&nbsp;Jan Schjøtt","doi":"10.2174/1574884714666181224144722","DOIUrl":"https://doi.org/10.2174/1574884714666181224144722","url":null,"abstract":"<p><strong>Background: </strong>Therapeutic drug monitoring is a relevant tool in drug treatment of elderly patients. The aim of this study was to assess the possibility of therapeutic drug monitoring of the most important potential interactions in nursing homes.</p><p><strong>Methods: </strong>A material of prescribed drugs to 446 patients in three nursing homes in Bergen, Norway from a single day in March 2016 was analysed. Clinically relevant drug interactions (pharmacodynamic or pharmacokinetic) were identified and classified with Stockley`s Interaction Alerts. The most important interaction among several in each patient were ranked by recommended action > severity > evidence according to Stockley`s. The possibility of therapeutic drug monitoring of drug combinations involved in the most important interactions was retrieved from a database of all laboratories performing clinical pharmacology in Norway (the Pharmacology Portal).</p><p><strong>Results: </strong>Two or more drugs were used by 443 (99.3%) of 446 patients. Three-hundred and eightyfour patients (86.1%) had > 1 interaction. About 95% of the most important interactions were pharmacodynamic. In 280 (72.9%) of these interactions, Stockley`s recommended adjust dose or monitoring. Among the 384 most important interactions, 93% involved one drug and 41% involved two drugs available for therapeutic drug monitoring.</p><p><strong>Conclusion: </strong>In this pilot study, therapeutic drug monitoring was possible in the majority of the most important interactions in Norwegian nursing homes. This option is of importance since adjust dose or monitoring were frequently recommended actions associated with these interactions.</p>","PeriodicalId":10746,"journal":{"name":"Current clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574884714666181224144722","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36813772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信